| Grant ID | DP220038 |
| Awarded On | August 17, 2022 |
| Title | Humanization, validation, and clinical translation of cell surface Heat shock protein 70-targeted antibody drug conjugates for T-cell non-Hodgkin lymphomas |
| Program | Product Development Research |
| Award Mechanism | Seed Awards for Product Development Research |
| Institution/Organization | Asylia Therapeutics |
| Principal Investigator/Program Director | John Miller |
| Cancer Sites | Breast, Lymphoma, Myeloma |
| Contracted Amount | $3,000,000 |
| Lay Summary |
Antibody-drug conjugates (ADCs) are an expanding class of highly effective cancer medicines. In ADCs, a toxic payload is conjugated to an antibody that recognizes a specific protein target selectively expressed on the surface of cancer cells. This results in the high concentration of toxin in tumors, while reducing toxicity to normal tissues. A long-sought goal has been to identify targets that are selectively expressed on the surface of a broad range of cancer but not normal cells. The scientific founders of Asylia discovered that the surface of many cancer cell types, but not normal cells, is decorated by Heat Shock Protein 70 (HSP70), where it can be targeted by antibodies loaded with can... |